Emergent BioSolutions (NYSE:EBS) Price Target Raised to $12.00 at Benchmark

Emergent BioSolutions (NYSE:EBS) had its price objective lifted by Benchmark from $8.00 to $12.00 in a research note issued to investors on Thursday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Separately, Rodman & Renshaw restated a “buy” rating and set a $16.00 price target on shares of Emergent BioSolutions in a research report on Friday, September 13th.

Emergent BioSolutions Price Performance

Shares of NYSE:EBS traded up $0.77 during trading on Thursday, reaching $11.77. The company had a trading volume of 2,168,164 shares, compared to its average volume of 1,163,124. Emergent BioSolutions has a 12 month low of $1.42 and a 12 month high of $15.10. The company has a current ratio of 1.06, a quick ratio of 0.54 and a debt-to-equity ratio of 1.16. The stock has a market capitalization of $622.75 million, a P/E ratio of -2.87 and a beta of 1.57. The company has a fifty day moving average of $8.43 and a two-hundred day moving average of $7.78.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Emergent BioSolutions in the 1st quarter valued at about $57,000. BNP Paribas Financial Markets lifted its position in Emergent BioSolutions by 155.3% in the first quarter. BNP Paribas Financial Markets now owns 163,589 shares of the biopharmaceutical company’s stock valued at $414,000 after purchasing an additional 99,520 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new position in shares of Emergent BioSolutions in the first quarter worth approximately $300,000. Vanguard Group Inc. increased its stake in shares of Emergent BioSolutions by 14.7% in the first quarter. Vanguard Group Inc. now owns 3,411,549 shares of the biopharmaceutical company’s stock worth $8,631,000 after buying an additional 436,911 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its holdings in Emergent BioSolutions by 22.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 23,943 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 4,409 shares during the last quarter. 78.40% of the stock is owned by hedge funds and other institutional investors.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.